145 related articles for article (PubMed ID: 18362220)
21. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
D'Andrea G; D'Ambrosio RL; Di Perna P; Chetta M; Santacroce R; Brancaccio V; Grandone E; Margaglione M
Blood; 2005 Jan; 105(2):645-9. PubMed ID: 15358623
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
Miyagata Y; Nakai K; Sugiyama Y
Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
[TBL] [Abstract][Full Text] [Related]
23. A new VKORC1 mutation leading to an isolated resistance to fluindione.
Peoc'h K; Pruvot S; Gourmel C; dit Sollier CB; Drouet L
Br J Haematol; 2009 Jun; 145(6):841-3. PubMed ID: 19344422
[No Abstract] [Full Text] [Related]
24. Pathology consultation on warfarin pharmacogenetic testing.
Stack G;
Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
[No Abstract] [Full Text] [Related]
25. Inherited warfarin resistance in Indian patients: does it occur?
Sharma V; Biswas A; Saxena R
Clin Appl Thromb Hemost; 2007 Oct; 13(4):455-6. PubMed ID: 17911202
[No Abstract] [Full Text] [Related]
26. The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.
Sominsky S; Korostishevsky M; Kurnik D; Aklillu E; Cohen Y; Ken-Dror G; Loebstein R; Halkin H; Gak E
J Appl Genet; 2014 May; 55(2):163-71. PubMed ID: 24425227
[TBL] [Abstract][Full Text] [Related]
27. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients.
Shrif NE; Won HH; Lee ST; Park JH; Kim KK; Kim MJ; Kim S; Lee SY; Ki CS; Osman IM; Rhman EA; Ali IA; Idris MN; Kim JW
Eur J Clin Pharmacol; 2011 Nov; 67(11):1119-30. PubMed ID: 21590310
[TBL] [Abstract][Full Text] [Related]
29. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
30. Genetic testing for warfarin dosing? Not yet ready for prime time.
Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
[No Abstract] [Full Text] [Related]
31. [Warfarin resistance and related pharmacogenetic information].
Takahashi H
Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
[TBL] [Abstract][Full Text] [Related]
32. A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance.
Ainle FN; Mumford A; Tallon E; McCarthy D; Murphy K
Ir J Med Sci; 2008 Jun; 177(2):159-61. PubMed ID: 18266023
[TBL] [Abstract][Full Text] [Related]
33. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
Loriot MA; Beaune P
Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomic testing for warfarin dosing: we are ready now.
Wu AH
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308
[No Abstract] [Full Text] [Related]
35. [Application of warfarin pharmacogenetics].
Tomek A; Mat'oska V; Kumstýrfová T; Táborský L
Vnitr Lek; 2009 Jun; 55(6):565-9. PubMed ID: 19662888
[TBL] [Abstract][Full Text] [Related]
36. Warfarin and pharmacogenomic testing: what would Pascal do?
Teagarden JR
Pharmacotherapy; 2009 Mar; 29(3):245-7. PubMed ID: 19249943
[No Abstract] [Full Text] [Related]
37. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Rost S; Fregin A; Ivaskevicius V; Conzelmann E; Hörtnagel K; Pelz HJ; Lappegard K; Seifried E; Scharrer I; Tuddenham EG; Müller CR; Strom TM; Oldenburg J
Nature; 2004 Feb; 427(6974):537-41. PubMed ID: 14765194
[TBL] [Abstract][Full Text] [Related]
38. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Limdi NA; Wadelius M; Cavallari L; Eriksson N; Crawford DC; Lee MT; Chen CH; Motsinger-Reif A; Sagreiya H; Liu N; Wu AH; Gage BF; Jorgensen A; Pirmohamed M; Shin JG; Suarez-Kurtz G; Kimmel SE; Johnson JA; Klein TE; Wagner MJ;
Blood; 2010 May; 115(18):3827-34. PubMed ID: 20203262
[TBL] [Abstract][Full Text] [Related]
39. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin.
Harv Heart Lett; 2007 Dec; 18(4):1-2. PubMed ID: 18219801
[No Abstract] [Full Text] [Related]
40. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
